Report ID [TBO/RPT/YYYY/NNNN]
Version [v1 · final]
Issued [DD Month YYYY]
info@tribro-omics.com · +91 86603 08678 · tribro-omics.com

CHALLENGE CARD

Reanalysis Report (Challenge Card)

Second-look analysis of a previous negative or inconclusive genomic test

1 Patient and sample

Patient name	[Surname, First name]
Patient ID / MRN	[ID]
Date of birth	[DD Month YYYY]
Sex	[Female / Male / Unknown]
Sample ID	[TBO-S-YYYY-NNNN]
Sample type	[EDTA blood / extracted DNA / saliva]
Collected	[DD Month YYYY]
Received	[DD Month YYYY]
Referring clinician	[Name, institution]
Clinical indication	[Phenotype summary; HPO terms, e.g. HP:0001250]

2 Test information

Product	Challenge Card — reanalysis of existing data
Genome build	GRCh38 [lifted over from GRCh37: yes / no]
Original test	[WES / WGS / panel], [laboratory], report date [DD Month YYYY]
Original result	[Negative / VUS / inconclusive]
Data received	[FASTQ / BAM / CRAM / VCF], [date]
Reason for reanalysis	[New symptoms / time since test / family request]

3 What changed since the original analysis

- [New gene–disease associations published since the original report]
- [Updated pipeline and variant callers]

- [Updated phenotype (HPO terms)]
- [Updated population and clinical databases]

4 Reanalysis findings

Gene	Transcript	Variant (HGVS)	Zygosity	Inheritance	Classification
[GENE]	[NM_ / MANE]	[c.] [p.]	[Het / Hom / Hemi]	[AD / AR / XL / de novo]	[Pathogenic / Likely path. / VUS]

5 Comparison with the original report

Variant	Original classification	Current classification	Reason for change
[GENE c.]	[VUS]	[Likely pathogenic]	[New evidence: ...]

OUTCOME

[New diagnostic finding / reclassification / no change: remains negative]

6 Interpretation

[Explain the clinical significance of the new findings and how they relate to the original result.]

7 Limitations

- Reanalysis depends on the quality and completeness of the data supplied; regions not covered in the original data cannot be assessed.
- Where only a VCF was supplied, variant calling could not be repeated.

8 Recommendations

- Discuss the outcome with the original laboratory and the referring clinician.
- Consider a further reanalysis in 12–24 months if the result remains negative.

9 Sign-off

Role	Name and qualification	Date
Analysed by (bioinformatics)	[Name, qualification]	[DD Month YYYY]
Reviewed by (clinical scientist)	[Name, qualification]	[DD Month YYYY]
Authorised by (laboratory director)	[Name, qualification]	[DD Month YYYY]

10 Important information

This report is intended for the referring clinician and must be interpreted together with the clinical findings, family history and other test results. Variant classification follows the ACMG/AMP 2015 standards (Richards et al., Genet Med 2015) and ClinGen Sequence Variant Interpretation recommendations. Classifications reflect the evidence available on the date of issue and may change. Genetic counselling is recommended when results are discussed with the patient. Report status: [Clinical / Research use only].